Siragen Pharmaceuticals has established a highly-focused drug discovery platform built on the company’s deep knowledge of synaptic damages triggered by Ca++ dyshomeostasis .
Siragen selective novel small molecules therapy may become a new treatment for progressive neurodegenerative changes at the synaptic and intra-neuronal levels. Its pharmacokinetic profiles is being optimized to drive a robust therapeutic response in various pre-clinical models of Alzheimer’s disease and aging disorders prior to its use in clinical trials.
Siragen’s target is central to pathways that trigger synaptic dysfunction leading to pathological landmarks of neuro-degenerative disorders. Siragen’s small molecules have been modeled based on intrasteric regulation using a structure-guided design, enhancing drastically the specificity and preventing action on downstream kinases.
Siragen’s novel drug design platform is also a paradigm shift for creating additional kinase inhibitors. Siragen’s new prototypes of kinase inhibitors can be applicable to a number of diseases in which auto-inhibitory dysfunction is the major mechanism of pathophysiology. At least three classes of diseases have been reported to be causally associated with aberrant kinase activity: central nervous system disorders (depression, schizophrenia), metabolic disorders (obesity and diabetes) and cancers (prostate, liver).